

Matthias Gromeier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9354136/publications.pdf>

Version: 2024-02-01

85
papers

3,477
citations

109321

35
h-index

149698

56
g-index

87
all docs

87
docs citations

87
times ranked

3606
citing authors

#	ARTICLE	IF	CITATIONS
1	Recurrent Glioblastoma Treated with Recombinant Poliovirus. <i>New England Journal of Medicine</i> , 2018, 379, 150-161.	27.0	570
2	Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	180
3	Dual Stem Loops within the Poliovirus Internal Ribosomal Entry Site Control Neurovirulence. <i>Journal of Virology</i> , 1999, 73, 958-964.	3.4	146
4	Poliovirus receptor CD155-targeted oncolysis of glioma. <i>Neuro-Oncology</i> , 2004, 6, 208-217.	1.2	116
5	Regulation of Eukaryotic Initiation Factor 4E (eIF4E) Phosphorylation by Mitogen-Activated Protein Kinase Occurs through Modulation of Mnk1-eIF4G Interaction. <i>Molecular and Cellular Biology</i> , 2010, 30, 5160-5167.	2.3	111
6	Mechanism of Injury-Provoked Poliomyelitis. <i>Journal of Virology</i> , 1998, 72, 5056-5060.	3.4	104
7	The Double-Stranded RNA Binding Protein 76:NF45 Heterodimer Inhibits Translation Initiation at the Rhinovirus Type 2 Internal Ribosome Entry Site. <i>Journal of Virology</i> , 2006, 80, 6936-6942.	3.4	98
8	The hepatitis C virus 3'-untranslated region or a poly(A) tract promote efficient translation subsequent to the initiation phase. <i>Nucleic Acids Research</i> , 2006, 34, 1293-1303.	14.5	80
9	Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 352.	12.8	77
10	Expression of the Human Poliovirus Receptor/CD155 Gene during Development of the Central Nervous System: Implications for the Pathogenesis of Poliomyelitis. <i>Virology</i> , 2000, 273, 248-257.	2.4	75
11	Recombinant Oncolytic Poliovirus Eliminates Glioma In Vivo Without Genetic Adaptation to a Pathogenic Phenotype. <i>Molecular Therapy</i> , 2008, 16, 1865-1872.	8.2	74
12	Cell-Type-Specific Repression of Internal Ribosome Entry Site Activity by Double-Stranded RNA-Binding Protein 76. <i>Journal of Virology</i> , 2006, 80, 3147-3156.	3.4	69
13	Oncolytic polio virotherapy of cancer. <i>Cancer</i> , 2014, 120, 3277-3286.	4.1	67
14	Expression of the Human Poliovirus Receptor/CD155 Gene Is Activated by Sonic Hedgehog. <i>Journal of Biological Chemistry</i> , 2002, 277, 25697-25702.	3.4	65
15	Phosphorylation of Eukaryotic Translation Initiation Factor 4G1 (eIF4G1) by Protein Kinase C β Regulates eIF4G1 Binding to Mnk1. <i>Molecular and Cellular Biology</i> , 2011, 31, 2947-2959.	2.3	57
16	MNK Controls mTORC1:Substrate Association through Regulation of TELO2 Binding with mTORC1. <i>Cell Reports</i> , 2017, 18, 1444-1457.	6.4	55
17	Activity of a type 1 picornavirus internal ribosomal entry site is determined by sequences within the 3' nontranslated region. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15125-15130.	7.1	53
18	Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. <i>Oncotarget</i> , 2016, 7, 79828-79841.	1.8	53

#	ARTICLE	IF	CITATIONS
19	Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. <i>Cytokine and Growth Factor Reviews</i> , 2010, 21, 197-203.	7.2	50
20	Treatment of Intracerebral Neoplasia and Neoplastic Meningitis with Regional Delivery of Oncolytic Recombinant Poliovirus. <i>Clinical Cancer Research</i> , 2004, 10, 4831-4838.	7.0	49
21	Recombinant Poliovirus for Cancer Immunotherapy. <i>Annual Review of Medicine</i> , 2018, 69, 289-299.	12.2	49
22	Attenuation of Neurovirulence, Biodistribution, and Shedding of a Poliovirus:Rhinovirus Chimera after Intrathalamic Inoculation in <i>Macaca fascicularis</i> . <i>Journal of Virology</i> , 2012, 86, 2750-2759.	3.4	48
23	Genetic Determinants of Cell Type-Specific Poliovirus Propagation in HEK 293 Cells. <i>Journal of Virology</i> , 2005, 79, 6281-6290.	3.4	47
24	Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. <i>Nature Communications</i> , 2021, 12, 1858.	12.8	47
25	Identification of Gemin5 as a Novel 7-Methylguanosine Cap-Binding Protein. <i>PLoS ONE</i> , 2009, 4, e7030.	2.5	46
26	The Polypyrimidine Tract Binding Protein Is Required for Efficient Picornavirus Gene Expression and Propagation. <i>Journal of Virology</i> , 2005, 79, 6172-6179.	3.4	45
27	Activation of cap-independent translation by variant eukaryotic initiation factor 4G in vivo. <i>Rna</i> , 2008, 14, 2170-2182.	3.5	45
28	Induction of Viral, 7-Methyl-Guanosine Cap-Independent Translation and Oncolysis by Mitogen-Activated Protein Kinase-Interacting Kinase-Mediated Effects on the Serine/Arginine-Rich Protein Kinase. <i>Journal of Virology</i> , 2014, 88, 13135-13148.	3.4	45
29	XIAP Regulation by MNK Links MAPK and NF κ B Signaling to Determine an Aggressive Breast Cancer Phenotype. <i>Cancer Research</i> , 2018, 78, 1726-1738.	0.9	45
30	Validation of an Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in Malignant Gliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 1697-1704.	2.5	44
31	Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma. , 2021, 9, e002203.		44
32	Mitogen-Activated Protein Kinase-Interacting Kinase Regulates mTOR/AKT Signaling and Controls the Serine/Arginine-Rich Protein Kinase-Responsive Type 1 Internal Ribosome Entry Site-Mediated Translation and Viral Oncolysis. <i>Journal of Virology</i> , 2014, 88, 13149-13160.	3.4	40
33	Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus. <i>Current Opinion in Virology</i> , 2015, 13, 81-85.	5.4	40
34	p38 δ Mitogen-Activated Protein Kinase Depletion and Repression of Signal Transduction to Translation Machinery by miR-124 and -128 in Neurons. <i>Molecular and Cellular Biology</i> , 2013, 33, 127-135.	2.3	39
35	A Small Yeast RNA Blocks Hepatitis C Virus Internal Ribosome Entry Site (HCV IRES)-Mediated Translation and Inhibits Replication of a Chimeric Poliovirus under Translational Control of the HCV IRES Element. <i>Journal of Virology</i> , 1998, 72, 5638-5647.	3.4	39
36	Poliovirus Receptor (CD155) Expression in Pediatric Brain Tumors Mediates Oncolysis of Medulloblastoma and Pleomorphic Xanthoastrocytoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 696-702.	1.7	38

#	ARTICLE	IF	CITATIONS
37	Competitive Translation Efficiency at the Picornavirus Type 1 Internal Ribosome Entry Site Facilitated by Viral cis and trans Factors. <i>Journal of Virology</i> , 2006, 80, 3310-3321.	3.4	35
38	Mitotic Phosphorylation of Eukaryotic Initiation Factor 4G1 (eIF4G1) at Ser1232 by Cdk1:Cyclin B Inhibits eIF4A Helicase Complex Binding with RNA. <i>Molecular and Cellular Biology</i> , 2014, 34, 439-451.	2.3	35
39	Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells. <i>Journal of Virology</i> , 2018, 92, .	3.4	35
40	MAPK Signal-integrating Kinase Controls Cap-independent Translation and Cell Type-specific Cytotoxicity of an Oncolytic Poliovirus. <i>Molecular Therapy</i> , 2010, 18, 1937-1946.	8.2	33
41	Poly(A)-binding protein is differentially required for translation mediated by viral internal ribosome entry sites. <i>Rna</i> , 2007, 13, 1582-1593.	3.5	31
42	Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. , 2019, 7, 142.		31
43	Dynamic Regulation of the Translation Initiation Helicase Complex by Mitogenic Signal Transduction to Eukaryotic Translation Initiation Factor 4G. <i>Molecular and Cellular Biology</i> , 2013, 33, 937-946.	2.3	30
44	Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. <i>Nature Communications</i> , 2020, 11, 524.	12.8	29
45	Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition. <i>Cancer Cell</i> , 2022, 40, 439-440.	16.8	27
46	Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay. <i>Journal of Virological Methods</i> , 2009, 155, 44-54.	2.1	26
47	Tissue Type-Specific Expression of the dsRNA-Binding Protein 76 and Genome-Wide Elucidation of Its Target mRNAs. <i>PLoS ONE</i> , 2010, 5, e11710.	2.5	22
48	Ribosomal RACK1:Protein Kinase C β II Modulates Intramolecular Interactions between Unstructured Regions of Eukaryotic Initiation Factor 4G (eIF4G) That Control eIF4E and eIF3 Binding. <i>Molecular and Cellular Biology</i> , 2018, 38, .	2.3	21
49	Regulation of Hypoxia-Inducible Factor 1 α during Hypoxia by DAP5-Induced Translation of PHD2. <i>Molecular and Cellular Biology</i> , 2018, 38, .	2.3	18
50	Enterovirus 2A ^{pro} Cleavage of the YTHDF m ⁶ A Readers Implicates YTHDF3 as a Mediator of Type I Interferon-Driven JAK/STAT Signaling. <i>MBio</i> , 2021, 12, .	4.1	18
51	Structural determinants of insert retention of poliovirus expression vectors with recombinant IRES elements. <i>Virology</i> , 2003, 311, 241-253.	2.4	17
52	Genetic Adaptation to Untranslated Region-Mediated Enterovirus Growth Deficits by Mutations in the Nonstructural Proteins 3AB and 3CD. <i>Journal of Virology</i> , 2007, 81, 8396-8405.	3.4	17
53	Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2061-2061.	1.6	17
54	Ribosomal RACK1:Protein Kinase C β II Phosphorylates Eukaryotic Initiation Factor 4G1 at S1093 To Modulate Cap-Dependent and -Independent Translation Initiation. <i>Molecular and Cellular Biology</i> , 2018, 38, .	2.3	16

#	ARTICLE	IF	CITATIONS
55	CReP mediates selective translation initiation at the endoplasmic reticulum. <i>Science Advances</i> , 2020, 6, eaba0745.	10.3	15
56	Aryl Hydrocarbon Receptor Signaling Controls CD155 Expression on Macrophages and Mediates Tumor Immunosuppression. <i>Journal of Immunology</i> , 2021, 206, 1385-1394.	0.8	15
57	Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors. <i>PLoS ONE</i> , 2019, 14, e0210608.	2.5	14
58	Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 717-732.	2.4	13
59	MNK inversely regulates TELO2 vs. DEPTOR to control mTORC1 signaling. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1306010.	0.7	12
60	Poliovirus and its cellular receptor: a molecular genetic dissection of a virus/receptor affinity interaction. , 1998, 11, 2-9.		11
61	Genetically Stable Picornavirus Expression Vectors with Recombinant Internal Ribosomal Entry Sites. <i>Journal of Virology</i> , 2002, 76, 8966-8972.	3.4	11
62	Determinants of Poliovirus Pathogenesis. , 0, , 367-379.		11
63	Oncolytic immunotherapy through tumor-specific translation and cytotoxicity of poliovirus. <i>Discovery Medicine</i> , 2015, 19, 359-65.	0.5	10
64	Attenuation of Herpes Simplex Virus Neurovirulence with Picornavirus cis -Acting Genetic Elements. <i>Journal of Virology</i> , 2007, 81, 791-799.	3.4	9
65	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2068-2068.	1.6	9
66	ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES. <i>Neuro-Oncology</i> , 2019, 21, vi7-vi7.	1.2	5
67	Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e12641-e12641.	1.6	5
68	The relation of prophylactic inoculations to the onset of poliomyelitis. , 1999, 9, 219-226.		4
69	AT-21 * FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM). <i>Neuro-Oncology</i> , 2014, 16, v13-v13.	1.2	4
70	Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2094-2094.	1.6	4
71	PKR Binds Enterovirus IRESs, Displaces Host Translation Factors, and Impairs Viral Translation to Enable Innate Antiviral Signaling. <i>MBio</i> , 0, , .	4.1	4
72	Harnessing virus tropism for dendritic cells for vaccine design. <i>Current Opinion in Virology</i> , 2020, 44, 73-80.	5.4	3

#	ARTICLE	IF	CITATIONS
73	HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN. <i>Neuro-Oncology</i> , 2018, 20, i93-i93.	1.2	2
74	Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2060-2060.	1.6	2
75	Oncolytic Viruses for Cancer Therapy. <i>American Journal of Cancer</i> , 2003, 2, 313-323.	0.4	1
76	Oncolytic viruses for the treatment of malignant glioma. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 363-371.	5.0	1
77	IMMU-34. ATRX MUTATIONS PREDICT RESPONSE TO INNATE BASED THERAPY IN GLIOMA. <i>Neuro-Oncology</i> , 2019, 21, vi126-vi126.	1.2	1
78	Safety and efficacy of murine PVSRIPO plus anti-PD-1 immune checkpoint inhibitor (ICI) in a melanoma tumor model.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2560-2560.	1.6	1
79	Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS2106-TPS2106.	1.6	1
80	ATIM-27. INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES. <i>Neuro-Oncology</i> , 2018, 20, vi7-vi7.	1.2	0
81	EXTH-51. GENETICALLY STABLE POLIOVIRUS VECTOR PLATFORM FOR DIPG IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2019, 21, vi93-vi93.	1.2	0
82	OTME-16. Polio virotherapy of murine brain tumors causes microglia/macrophage proliferation and inflammation that is potentiated by immune checkpoint blockade. <i>Neuro-Oncology Advances</i> , 2021, 3, ii17-ii17.	0.7	0
83	Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG).. <i>Journal of Clinical Oncology</i> , 2017, 35, e13533-e13533.	1.6	0
84	IMMU-18. INTERPLAY BETWEEN IDH1 AND ATRX MUTATIONS GOVERN INNATE IMMUNE RESPONSES IN GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii108-ii108.	1.2	0
85	TMOD-17. ONCOLYTIC POLIOVIRUS AS A PROBE FOR MECHANISMS OF IMMUNE RESISTANCE IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii231-ii231.	1.2	0